
Double first for Scotland as it backs Roche’s Rozlytrek, Nov...
The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK gene fusion mutations, regardless of where they o